Alerts will be sent to your verified email
Verify Email
NOVARTIND
|
Novartis
|
Indoco Remedies
|
Beta Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
-5.28 % | -4.3 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
5.71 % | 11.09 % | 21.73 % |
|
5yr average Equity Multiplier
|
2.57 | 1.79 | 1.75 |
|
5yr Average Asset Turnover Ratio
|
0.22 | 0.92 | 1.04 |
|
5yr Avg Net Profit Margin
|
11.91 % | 6.73 % | 11.97 % |
|
Price to Book
|
2.79 | 2.02 | 0.0 |
|
P/E
|
23.62 | 0.0 | 51.48 |
|
5yr Avg Cash Conversion Cycle
|
-22.58 Days | 53.79 Days | 15.7 Days |
|
Inventory Days
|
44.4 Days | 66.59 Days | 43.83 Days |
|
Days Receivable
|
38.62 Days | 76.04 Days | 87.61 Days |
|
Days Payable
|
118.8 Days | 121.65 Days | 113.94 Days |
|
5yr Average Interest Coverage Ratio
|
32.45 | 7.97 | 13.71 |
|
5yr Avg ROCE
|
4.99 % | 15.12 % | 27.85 % |
|
5yr Avg Operating Profit Margin
|
10.55 % | 15.97 % | 21.58 % |
|
5 yr average Debt to Equity
|
0.0 | 0.38 | 0.23 |
|
5yr CAGR Net Profit
|
53.24 % | 32.49 % | 31.07 % |
|
5yr Average Return on Assets
|
2.24 % | 6.31 % | 12.53 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.68 % | 58.9 % | 66.73 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.21 % | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 1.0 % | 0.0 |
|
Novartis
|
Indoco Remedies
|
Beta Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|